


Gedatolisib

Chemical Properties

CAS No. : 1197160-78-3
Formula: C32H41N9O4
Molecular Weight: 615.73
Appearance: no data available
Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year



Biological Description

Description	Gedatolisib (PF-05212384) is a highly effective dual inhibitor targeting the PI3K α / γ (IC50: 0.4/5.4 nM) and mTOR (IC50: 1.6 nM) in the PI3K/mTOR signaling pathway.
Targets(IC50)	PI3K, mTOR
In vitro	In a xenograft model of H1975 non-small cell lung cancer (NSCLC) with EGFR mutations (L858R, T790M), treatment with PKI-587 at a dose of 25 mg/kg for seven days resulted in a 90% survival rate in the experimental group. PKI-587 administration (25 mg/kg, intravenously) in nude mice showed a high volume of distribution (7.2 L/kg), low plasma clearance rate (7 mL/min/kg), and an extended half-life (14.4 hours). In the MDA-361 xenograft tumor model, PKI-587 demonstrated significant antitumor activity, with the lowest effective dose being 3 mg/kg and the maximum tolerated dose at 30 mg/kg.
In vivo	In both the MDA-361 and PC3-MM2 cell lines, PKI-587 exhibits inhibitory effects on tumor cell growth, with IC50 values of 4 and 13.1 nM, respectively. Additionally, PKI-587 is effective against mutations in PI3K α , particularly the H1047R and E545K mutations, displaying IC50 values of 0.6 nM for both.
Kinase Assay	PI3K and mTOR kinase assay : Enzyme assays are done in fluorescent polarization (FP) format, adapted from the Echelon K-1100 PI3K FP assay kit protocol. Human class I PI3Ks and PI3K- α mutants (E545K and H1047R) are produced in Sf9 or purchased from Upstate Biotech. GST-GRP1 (murine) is produced in Escherichia coli and isolated by GST-Sepharose. Assay buffers are reaction buffer [20 mM HEPES (pH 7.1), 2 mM MgCl ₂ , 0.05% CHAPS, and 0.01% β -mercaptoethanol] and stop/detection buffer [100 mM HEPES (pH 7.5), 4 mM EDTA, 0.05% CHAPS]. FP reaction is run for 30 minutes at room temperature in 20 μ L of reaction buffer containing 20 μ M phosphatidylinositol 4,5-bisphosphate (PIP ₂), 25 μ M ATP, and <4% DMSO. FP reaction is stopped with 20 μ L of stop/detection buffer (10 nM probe and 40 nM GST-GRP), and after 2 hours, data are collected using an Envision plate reader. The routine assays with purified FLAG-TOR (FL and 3.5) are performed in 96-well plates as follows. Enzymes are first diluted in kinase assay buffer (10 mM Hepes (pH 7.4), 50 mM NaCl, 50 mM β -glycerophosphate, 10 mM MnCl ₂ , 0.5 mM DTT, 0.25 μ M microcystin LR, and 100 μ g/mL BSA). To each well, 12 μ L of the diluted enzyme is mixed briefly with 0.5 μ L test inhibitor or control vehicle dimethyl sulfoxide (DMSO). The kinase reaction is initiated by adding 12.5 μ L kinase assay buffer containing ATP and His6-S6K to give a final reaction volume of 25 μ L containing 800 ng/mL FLAG-TOR, 100 μ M ATP, and 1.25 μ M His6-S6K. The reaction plate is incubated for 2 hours

(linear at 1-6 hours) at room temperature with gentle shaking and then terminated by adding 25 μ L Stop buffer (20 mM Hepes (pH 7.4), 20 mM EDTA, and 20 mM EGTA).

Cell Research

Cells are plated in 96-well culture plates at about 3000 cells per well. One day following plating, PKI-587 is added to cells. Three days after PKI-587 treatment, viable cell densities are determined by measuring metabolic conversion (by viable cells) of the dye MTS, a previously established cell proliferation assay. For each assay, MTS and PMS stocks are freshly thawed and mixed (MTS/PMS, 20:1). The MTS/PMS mixture is then added to 96-well cell plates at 20 μ L/well, and plates are incubated for 1 hour-2 hours in cell culture incubator. MTS assay results are read in a 96-well format plate reader by measuring absorbance at 490 nm. The effect of each PKI-587 treatment is calculated as a percentage of control cell growth obtained from vehicle-treated cells grown in the same culture plate.(Only for Reference)

Solubility Information

Solubility

DMSO: < 1mg/ml (insoluble) ,
(< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.6241 mL	8.1204 mL	16.2409 mL
5 mM	0.3248 mL	1.6241 mL	3.2482 mL
10 mM	0.1624 mL	0.812 mL	1.6241 mL
50 mM	0.0325 mL	0.1624 mL	0.3248 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Venkatesan AM, et al. J Med Chem. 2010, 53(6), 2636-2645.
Gedaly R, et al. J Surg Res. 2011, doi.org/10.1016/j.jss.2011.10.045.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only· Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481